Share on StockTwits

Jefferies Group lowered their price objective on shares of Heron Therapeutics (NASDAQ:HRTX) from $20.00 to $18.00 in a research note issued on Friday, Analyst RN reports. Jefferies Group’s target price suggests a potential upside of 59.15% from the company’s current price.

Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 11.31 on Friday. Heron Therapeutics has a 1-year low of $0.44 and a 1-year high of $15.82. The stock has a 50-day moving average of $12.79 and a 200-day moving average of $11.27. The company’s market cap is $268.3 million.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.74) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.67) by $0.07. On average, analysts predict that Heron Therapeutics will post $-3.16 earnings per share for the current fiscal year.

A number of other analysts have also recently weighed in on HRTX. Analysts at JMP Securities raised their price target on shares of Heron Therapeutics from $16.00 to $20.00 in a research note on Thursday, March 6th. They now have an “outperform” rating on the stock. Analysts at Zacks downgraded shares of Heron Therapeutics to a “neutral” rating in a research note on Monday, February 24th. They now have a $14.30 price target on the stock. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Heron Therapeutics currently has an average rating of “Buy” and an average price target of $17.43.

Heron Therapeutics Inc, formerly A.P. Pharma, Inc is a specialty pharmaceutical company developing pharmaceutical products using its Biochronomer polymer-based drug delivery platform.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.